Pelthos Therapeutics Names New CFO Amid Growth Push
Event summary
- John M. Gay appointed CFO of Pelthos Therapeutics effective April 10, 2026, succeeding Francis Knuettel II.
- Gay previously served as Senior Vice President, Finance & Accounting at Pelthos since 2025.
- Gay brings over 25 years of public company finance experience, including CFO roles at LNHC and Furiex Pharmaceuticals.
- Knuettel led Pelthos through merger with Channel Therapeutics and two significant capital raises.
The big picture
Pelthos Therapeutics' CFO transition comes as the company seeks to capitalize on its commercial-stage portfolio, including ZELSUVMI for Molluscum contagiosum and other dermatological treatments. The move follows a period of significant capital raises and operational scaling, highlighting the importance of financial leadership in navigating growth phases. The biopharmaceutical sector's focus on innovative therapies for unmet needs makes Pelthos' strategic moves particularly noteworthy.
What we're watching
- Execution Risk
- How John Gay's transition will impact Pelthos' commercial momentum and growth strategy.
- Governance Dynamics
- Whether the leadership change signals a shift in strategic direction or operational focus.
- Market Positioning
- The pace at which Pelthos can sustain its growth trajectory in the competitive biopharmaceutical sector.
Related topics